Bioengineering Strategies for Developing Vaccines
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 30 June 2026 | Viewed by 5891
Special Issue Editors
Interests: vaccine immunology; viral immunology; B cells; host–virus interactions
Special Issue Information
Dear Colleagues,
In the past few years, we have witnessed a remarkable stride in vaccine development, which was driven by a rapid response to the SARS-CoV-2 pandemic. Along with this evolution, bioengineering has seen more integration into vaccine development than ever before. Genetic engineering enables the creation of antigens that are tailored to elicit stronger desired immune responses. Gene editing has become a common tool in exploring vaccine platforms, while biomaterials and nanotechnology continue to add new ingredients to improve antigen stability, as well as vaccine release and delivery. Additionally, microfluidic devices have emerged as an effective way to enhance immune response in a targeted, controlled manner.
For this Special Issue, we are calling for research papers and reviews related to the bioengineering of vaccines, including, but not limited to, antigen engineering, vaccine platform development, vaccine delivery systems, and the application of artificial intelligence to vaccine design. We hope this Special Issue provides an opportunity to learn about updated bioengineering advances in vaccine development, both innovative methods and real-world applications, for advancing vaccine efficacy and safety.
Prof. Dr. Chen Zhao
Dr. Jiayi Shu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccine platform
- antigen design
- targeted delivery
- mRNA
- nanoparticle
- artificial intelligence
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
